Submission of audited financial results for the quarter and financial year ended 3st March 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Johnson Pharmacare Ltd reported a massive net loss of ₹5,573.39 Lacs for FY2026, compared to a loss of ₹58.38 Lacs in the previous year. Total income was ₹158.10 Lacs while total expenses stood at ₹4,304.49 Lacs. The company incurred exceptional items of ₹1,427.00 Lacs and reported negative other equity of ₹5,456.48 Lacs. Cash losses amounted to ₹11,123.52 Lacs. The auditors from VRSK & Associates issued a qualified opinion citing non-compliance with Ind AS, non-provision of interest on loans, and qualified opinion on internal financial controls. The company has borrowings of ₹2,140.19 Lacs and pending tax demands including ₹233.02 Lacs from AY 1996-97. There was also a change in auditors during the year.
The company is in severe financial distress with massive losses, negative equity, and auditor concerns about ability to meet short-term liabilities. Shareholders should be extremely cautious as the company faces going concern risks despite auditor's nominal statement otherwise.